96 related articles for article (PubMed ID: 26662954)
41. CD44 rs13347 C>T polymorphism predicts breast cancer risk and prognosis in Chinese populations.
Jiang L; Deng J; Zhu X; Zheng J; You Y; Li N; Wu H; Lu J; Zhou Y
Breast Cancer Res; 2012 Jul; 14(4):R105. PubMed ID: 22788972
[TBL] [Abstract][Full Text] [Related]
42. Common cancer stem cell gene variants predict colon cancer recurrence.
Gerger A; Zhang W; Yang D; Bohanes P; Ning Y; Winder T; LaBonte MJ; Wilson PM; Benhaim L; Paez D; El-Khoueiry R; El-Khoueiry A; Kahn M; Lenz HJ
Clin Cancer Res; 2011 Nov; 17(21):6934-43. PubMed ID: 21918173
[TBL] [Abstract][Full Text] [Related]
43. Significance of site-specific prognosis of cancer stem cell marker CD44 in head and neck squamous-cell carcinoma.
Kokko LL; Hurme S; Maula SM; Alanen K; Grénman R; Kinnunen I; Ventelä S
Oral Oncol; 2011 Jun; 47(6):510-6. PubMed ID: 21514878
[TBL] [Abstract][Full Text] [Related]
44. CD44 splice isoform switching in human and mouse epithelium is essential for epithelial-mesenchymal transition and breast cancer progression.
Brown RL; Reinke LM; Damerow MS; Perez D; Chodosh LA; Yang J; Cheng C
J Clin Invest; 2011 Mar; 121(3):1064-74. PubMed ID: 21393860
[TBL] [Abstract][Full Text] [Related]
45. CD44: can a cancer-initiating cell profit from an abundantly expressed molecule?
Zöller M
Nat Rev Cancer; 2011 Apr; 11(4):254-67. PubMed ID: 21390059
[TBL] [Abstract][Full Text] [Related]
46. Role of hyaluronan-mediated CD44 signaling in head and neck squamous cell carcinoma progression and chemoresistance.
Wang SJ; Bourguignon LY
Am J Pathol; 2011 Mar; 178(3):956-63. PubMed ID: 21356346
[TBL] [Abstract][Full Text] [Related]
47. Global cancer statistics.
Jemal A; Bray F; Center MM; Ferlay J; Ward E; Forman D
CA Cancer J Clin; 2011; 61(2):69-90. PubMed ID: 21296855
[TBL] [Abstract][Full Text] [Related]
48. Germline polymorphisms in genes involved in the CD44 signaling pathway are associated with clinical outcome in localized gastric adenocarcinoma.
Winder T; Ning Y; Yang D; Zhang W; Power DG; Bohanes P; Gerger A; Wilson PM; Lurje G; Tang LH; Shah M; Lenz HJ
Int J Cancer; 2011 Sep; 129(5):1096-104. PubMed ID: 21105049
[TBL] [Abstract][Full Text] [Related]
49. Unique SNP in CD44 intron 1 and its role in breast cancer development.
Zhou J; Nagarkatti PS; Zhong Y; Creek K; Zhang J; Nagarkatti M
Anticancer Res; 2010 Apr; 30(4):1263-72. PubMed ID: 20530438
[TBL] [Abstract][Full Text] [Related]
50. Chemosensitivity profiles identify polymorphisms in the p53 network genes 14-3-3tau and CD44 that affect sarcoma incidence and survival.
Vazquez A; Grochola LF; Bond EE; Levine AJ; Taubert H; Müller TH; Würl P; Bond GL
Cancer Res; 2010 Jan; 70(1):172-80. PubMed ID: 19996285
[TBL] [Abstract][Full Text] [Related]
51. A case-control study of smoking and bladder cancer risk: emergent patterns over time.
Baris D; Karagas MR; Verrill C; Johnson A; Andrew AS; Marsit CJ; Schwenn M; Colt JS; Cherala S; Samanic C; Waddell R; Cantor KP; Schned A; Rothman N; Lubin J; Fraumeni JF; Hoover RN; Kelsey KT; Silverman DT
J Natl Cancer Inst; 2009 Nov; 101(22):1553-61. PubMed ID: 19917915
[TBL] [Abstract][Full Text] [Related]
52. CD44 and EpCAM: cancer-initiating cell markers.
Marhaba R; Klingbeil P; Nuebel T; Nazarenko I; Buechler MW; Zoeller M
Curr Mol Med; 2008 Dec; 8(8):784-804. PubMed ID: 19075676
[TBL] [Abstract][Full Text] [Related]
53. The epithelial-mesenchymal transition generates cells with properties of stem cells.
Mani SA; Guo W; Liao MJ; Eaton EN; Ayyanan A; Zhou AY; Brooks M; Reinhard F; Zhang CC; Shipitsin M; Campbell LL; Polyak K; Brisken C; Yang J; Weinberg RA
Cell; 2008 May; 133(4):704-15. PubMed ID: 18485877
[TBL] [Abstract][Full Text] [Related]
54. Expression of CD44s and CD44v6 in transitional cell carcinomas of the urinary bladder: comparison with tumour grade, proliferative activity and p53 immunoreactivity of tumour cells.
Kuncová J; Urban M; Mandys V
APMIS; 2007 Nov; 115(11):1194-205. PubMed ID: 18092951
[TBL] [Abstract][Full Text] [Related]
55. Silent polymorphisms speak: how they affect pharmacogenomics and the treatment of cancer.
Sauna ZE; Kimchi-Sarfaty C; Ambudkar SV; Gottesman MM
Cancer Res; 2007 Oct; 67(20):9609-12. PubMed ID: 17942888
[TBL] [Abstract][Full Text] [Related]
56. Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma.
Prince ME; Sivanandan R; Kaczorowski A; Wolf GT; Kaplan MJ; Dalerba P; Weissman IL; Clarke MF; Ailles LE
Proc Natl Acad Sci U S A; 2007 Jan; 104(3):973-8. PubMed ID: 17210912
[TBL] [Abstract][Full Text] [Related]
57. Association of interleukin-1Ra gene polymorphism in patients with bladder cancer: case control study from North India.
Bid HK; Manchanda PK; Mittal RD
Urology; 2006 May; 67(5):1099-104. PubMed ID: 16698387
[TBL] [Abstract][Full Text] [Related]
58. Does occupational exposure to PAHs, diesel and aromatic amines interact with smoking and metabolic genetic polymorphisms to increase the risk on bladder cancer?; The Belgian case control study on bladder cancer risk.
Kellen E; Zeegers M; Paulussen A; Vlietinck R; Vlem EV; Veulemans H; Buntinx F
Cancer Lett; 2007 Jan; 245(1-2):51-60. PubMed ID: 16504378
[TBL] [Abstract][Full Text] [Related]
59. The emerging role of CD44 in regulating skeletal micrometastasis.
Hill A; McFarlane S; Johnston PG; Waugh DJ
Cancer Lett; 2006 Jun; 237(1):1-9. PubMed ID: 15979783
[TBL] [Abstract][Full Text] [Related]
60. Expression of CD44v6 correlates with cell proliferation and cellular atypia in urothelial carcinoma cell lines 5637 and HT1197.
Kuncová J; Kostrouch Z; Viale M; Revoltella R; Mandys V
Folia Biol (Praha); 2005; 51(1):3-11. PubMed ID: 15783086
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
